Renal cell carcinoma
Rosetta Genomics, developer and provider of microRNA-based and other molecular diagnostics, announced today that the United States Patent and Trademark Office has granted a patent for its gene expression signature test for classifying kidney tumors.
In particular, Rosetta is looking to distinguish these four types of kidney cancer: oncocytoma, clear cell renal cell carcinoma (RCC), papillary RCC, and chromophobe RCC.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
“Kidney cancer is among the 10 most common cancers in both men and women with approximately 61,000 new cases of primary kidney tumors and 14,000 deaths per year in the U.S.,” Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics, said in a statement. “Unfortunately the incidence of primary kidney tumors is rising and so is the number of biopsies, yet differential diagnosis between various types of kidney tumors has been challenging.
The ability to more accurately define the different types of cancer could lead to lowering costs for treatment and reducing complications. Being able to identify the particular type of cancer and how aggressive it is in this area would be significant for therapy options.
Photo: from Wikipedia
